Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone to prevent radiation-induced lung injury in unresectable esophageal cancer
ChiCTR2100043032Phase 4Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in radiation-induced lung injury (RILI) comparing Pirfenidone with Placebo (2 arms). Primary endpoint: Incidence of grade ≥2 radiation-induced lung injury. Started Nov 2021; status: recruiting.
02
Drugs
pirfenidone
03
Conditions
radiation-induced lung injury (RILI)
Beyond the preview
Go deeper on ChiCTR2100043032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043032.